8-K: Tivic Health Transforms to Immunotherapy, Reports 2025 Results

Tivic Health Systems, Inc. announced its strategic shift to an immunotherapy company, focusing on its Entolimod platform and reporting increased net losses for 2025.

Summary

• Completed strategic transformation into a focused immunotherapy company, centered on the Entolimod platform and its next-generation molecule, Entolasta.
• Secured exclusive global rights to Entolimod for acute radiation syndrome (ARS), including a comprehensive development package.
• Engaged with U.S. government agencies (BARDA, DTRA, NIH, NIAID) regarding potential development funding and Strategic National Stockpile procurement of Entolimod for ARS.
• Acquired biomanufacturing assets to establish Velocity Bioworks, a wholly owned Contract Development and Manufacturing Organization (CDMO) subsidiary, hiring 45 employees in December 2025.
• Discontinued ClearUP operations and suspended the non-core neuromodulation program, exiting the consumer product business.
• Relocated corporate headquarters to San Antonio, Texas.
• Operating expenses increased to $7.9 million in 2025 from $4.5 million in 2024, primarily due to the introduction of the biopharma business and CDMO operations.
• Net loss before discontinued operations is expected to be in the range of $7.9 million to $8.1 million for 2025, up from $4.5 million in 2024.
• Total net loss is expected to be in the range of $8.8 million to $9.1 million for 2025, compared to $5.7 million in 2024.
• Cash and equivalents significantly increased to $12.6 million at December 31, 2025, from $2.0 million at December 31, 2024.
• Working capital stood at $12.4 million at year-end 2025.
• Finalizing accounting for a $16.3 million Senior Secured Convertible Note Payable dated December 10, 2025, with proceeds used for Velocity Bioworks assets.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive report given the significant strategic transformation and progress in drug development and CDMO establishment, despite increased losses typical for a development-stage company.

Positives

• Successful strategic transformation into a focused immunotherapy company.
• Secured exclusive global rights to Entolimod, a promising candidate for acute radiation syndrome (ARS) with Fast Track and Orphan Drug designations.
• Initiated discussions with U.S. government agencies (BARDA, DTRA, NIH, NIAID) for potential funding and Strategic National Stockpile procurement of Entolimod.
• Established Velocity Bioworks, a CDMO subsidiary, which provides vertical integration, reduces manufacturing costs and timelines, and creates a new potential revenue stream from third-party projects.
• Significant increase in cash and equivalents to $12.6 million at year-end 2025 from $2.0 million in 2024, providing a stronger liquidity position.
• Working capital of $12.4 million at year-end 2025.
• Advancing Entolimod for oncology supportive care, targeting Neutropenia, with physician-sponsored clinical trials expected later this year.

Negatives

• Operating expenses increased significantly to $7.9 million in 2025 from $4.5 million in 2024.
• Net loss before discontinued operations is expected to increase to $7.9 million $8.1 million in 2025 from $4.5 million in 2024.
• Total net loss is expected to increase to $8.8 million $9.1 million in 2025 from $5.7 million in 2024.
• The company is still in the development stage and has not yet generated significant revenue from its new core business.
• Finalizing accounting matters related to the $16.3 million Senior Secured Convertible Note Payable, which could indicate complexity or ongoing adjustments.

Risks

• Uncertainty regarding interactions with and guidance from the FDA and other regulatory authorities.
• Continued interest of BARDA and other U.S. government agencies in Entolimod is not guaranteed.
• Ability to achieve expected benefits from the acquisition of development and manufacturing assets within expected time frames or at all.
• Changes to the company's relationship with its partners.
• Failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations, including related to the Animal Rule.
• Uncertainty regarding the company's future development of Entolimod or Entolasta.
• Changes to the company's business strategy.
• Timing and success of pre-clinical and clinical trials and study results.
• Regulatory requirements and pathways for approval.
• Ability to successfully commercialize product candidates in the future.
• Changes in the markets and industries in which the company does business.
• Consummation of any strategic transactions.
• Need for, and ability to secure when needed, additional working capital.
• Ability to maintain Nasdaq listing.
• Changes in tariffs, inflation, legal, regulatory, political, and economic risks.

Future Outlook

The company is optimistic that ongoing discussions with BARDA, the Department of War, and NIAID will advance toward potential funding or sponsorship for Entolimod as a medical countermeasure. The Neutropenia program is on track to advance into physician-sponsored clinical trials later this year. Velocity Bioworks is positioned to create a new revenue stream by servicing third-party development projects, supporting the long-term objective of transforming manufacturing capabilities into a high-margin profit center.

Management Comments

• "2025 was a defining year for Tivic as we marked our transformation into a focused immunotherapy company anchored by Entolimod and its next-generation molecule, Entolasta."
• "During the year, we secured global rights to Entolimod and advanced regulatory and development readiness, while initiating discussions with U.S. government agencies regarding its potential as a medical countermeasure."
• "Entolimod's differentiated cytoprotective properties, immune-enhancing mechanism, and extensive development history make it a promising candidate for national preparedness programs."
• "We are optimistic that our ongoing discussions with BARDA, the Department of War, and the National Institute of Allergy and Infectious Disease will advance toward a potential funding or sponsorship arrangement."
• "While Entolimod for acute radiation syndrome remains our lead indication, its development is the first phase of a broader strategic roadmap to penetrate the multi-billion-dollar oncology supportive care market."
• "Our immediate focus is on Neutropenia, where we are targeting the severe and often fatal side effects of chemo and radiation therapy. We are on track to advance this program into physician-sponsored clinical trials later this year."
• "Simultaneously, the vertical integration provided by Velocity Bioworks has already significantly reduced our manufacturing timelines and costs."
• "Beyond internal efficiencies, we have positioned Velocity Bioworks as a standalone contract development and manufacturing organization, or CDMO, to service third-party development projects. This creates an immediate opportunity for a new revenue stream and supports our long-term objective of transforming our manufacturing capabilities into a high margin profit center for the broader biotech industry."

Industry Context

StockSavvy.ai notes that Tivic Health's strategic pivot into immunotherapy and the CDMO space aligns with broader trends in the biotech industry, where specialized drug development and outsourced manufacturing services are in high demand. The focus on acute radiation syndrome and oncology supportive care addresses critical unmet medical needs, potentially positioning Entolimod for significant government and commercial interest. The establishment of Velocity Bioworks as a CDMO also taps into the growing market for biomanufacturing, offering a diversified revenue stream beyond drug development.

Comparison to Industry Standards

• The strategic shift to immunotherapy and CDMO services is a common strategy for smaller biotech firms seeking to leverage specialized assets and diversify revenue, similar to how companies like Catalent or Lonza operate on a larger scale in the CDMO market, or how emerging biotechs often focus on niche indications with high unmet needs.
• Entolimod's Fast Track and Orphan Drug designations from the FDA are positive indicators, often seen in successful development programs for rare diseases or conditions with limited treatment options, such as those pursued by companies like Sarepta Therapeutics or Alexion Pharmaceuticals.
• Discussions with U.S. government agencies like BARDA for medical countermeasures are typical for drugs addressing national security threats, akin to contracts awarded to companies developing vaccines or treatments for biodefense, such as Emergent BioSolutions.
• The significant increase in net loss and operating expenses is typical for a development-stage biopharma company undergoing a major strategic transformation and investing heavily in R&D and infrastructure, which is common for peers in the early clinical stages.
• The substantial increase in cash and working capital, largely from the $16.3 million convertible note, provides a stronger financial runway, which is crucial for development-stage companies, though the convertible nature of the debt introduces potential dilution.

Management Changes

Stakeholder Impact

• Shareholders: Potential for long-term value creation through the strategic pivot to immunotherapy and CDMO, but also increased short-term losses and potential dilution from the convertible note.
• Employees: 45 new employees hired for Velocity Bioworks, indicating growth in that segment; relocation of corporate headquarters may impact existing employees.
• Customers (future): Potential for new customers for Velocity Bioworks' CDMO services.
• Government Agencies: Ongoing engagement with BARDA, DTRA, NIH, NIAID for potential funding and procurement of Entolimod.
• Creditors: The $16.3 million Senior Secured Convertible Note Payable represents a significant debt obligation.

Next Steps

• Advance discussions with U.S. government agencies (BARDA, Department of War, NIAID) for potential funding or sponsorship of Entolimod.
• Advance the Neutropenia program into physician-sponsored clinical trials later this year.
• Finalize accounting matters related to the $16.3 million Senior Secured Convertible Note Payable.
• File the Annual Report on Form 10-K for the year ended December 31, 2025, on or before March 31, 2026.
• Continue to position Velocity Bioworks as a standalone CDMO to service third-party development projects and generate new revenue streams.

Key Dates

Recommendation

The company has undergone a significant strategic transformation with promising drug candidates and a new CDMO revenue stream, which are positive long-term developments. However, the increased net losses and operating expenses reflect the early stage of this pivot, and future success hinges on securing government funding, successful clinical trials, and effective commercialization. The convertible note also introduces potential dilution. Given the early stage of the new strategy and the associated risks, a 'hold' recommendation is appropriate for investors to monitor progress before making further commitments.

Keywords

Immunotherapy, Entolimod, Acute Radiation Syndrome, ARS, Neutropenia, Oncology Supportive Care, Biopharma, CDMO, Velocity Bioworks, TLR5 Agonist, FDA Fast Track, Orphan Drug, BARDA, Biomanufacturing, Clinical Trials, TIVC